Halozyme Therapeutics Operating Expense Breakdown

History

Date	Cost of Sales	Selling, General, and Administrative	Research and Development	Amortization
Sep 30, 2024	169.66M	149.69M	79.94M	71.05M
Jun 30, 2024	175.06M	143.72M	78.81M	73.63M
Mar 31, 2024	185.52M	146.96M	77.50M	73.70M
Dec 31, 2023	192.36M	149.18M	76.36M	73.77M
Sep 30, 2023	182.18M	149.32M	77.59M	60.56M
Jun 30, 2023	174.68M	148.52M	76.98M	67.42M
Mar 31, 2023	158.55M	167.05M	72.73M	60.98M
Dec 31, 2022	139.30M	143.53M	66.61M	43.15M
Sep 30, 2022	118.77M	119.55M	54.15M	38.60M
Jun 30, 2022	90.04M	98.25M	45.93M	11.40M
Mar 31, 2022	79.12M	53.10M	38.52M	-
Dec 31, 2021	81.41M	50.32M	35.67M	-
Sep 30, 2021	86.10M	46.98M	32.94M	-
Jun 30, 2021	73.08M	45.51M	32.21M	-
Mar 31, 2021	55.80M	44.16M	33.09M	-
Dec 31, 2020	43.37M	45.74M	34.24M	-
Sep 30, 2020	33.78M	59.24M	71.97M	-
Jun 30, 2020	50.55M	65.52M	94.68M	-
Mar 31, 2020	46.68M	71.88M	119.63M	-
Dec 31, 2019	45.55M	77.25M	140.80M	-

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.